Efficacy of Every Four Monthly and Quarterly Dosing of Faricimab vs Ranibizumab in Neovascular Age-Related Macular Degeneration-Reference-Cited by-同舟云学术

Efficacy of Every Four Monthly and Quarterly Dosing of Faricimab vs Ranibizumab in Neovascular Age-Related Macular Degeneration

Published:2020-09-01 Issue:9 Volume:138 Page:964
ISSN:2168-6165
Container-title:JAMA Ophthalmology
language:en
Short-container-title:JAMA Ophthalmol

Author:

Khanani Arshad M.¹²,Patel Sunil S.³,Ferrone Philip J.⁴,Osborne Aaron⁵⁶,Sahni Jayashree⁷,Grzeschik Susanna⁵,Basu Karen⁵⁸,Ehrlich Jason S.⁵⁹,Haskova Zdenka⁵,Dugel Pravin U.¹⁰¹¹¹²

Affiliation:

1. Sierra Eye Associates, Reno, Nevada

2. Reno School of Medicine, University of Nevada, Reno

3. West Texas Retina Consultants, Abilene

4. Long Island and Queens Vitreoretinal Consultants, PC, Great Neck, New York

5. Genentech Inc, South San Francisco, California

6. now with Adverum Biotechnologies Inc, Menlo Park, California

7. Roche Innovation Center Basel, Roche Pharma Research and Early Development, F. Hoffmann-La Roche, Basel, Switzerland

8. now with Roche Products (Ireland), Dublin, Ireland

9. now with Kodiak Sciences Inc, Palo Alto, California

10. Retinal Consultants of Arizona, Phoenix

11. USC Roski Eye Institute, Keck School of Medicine, University of Southern California, Los Angeles

12. now with IVERIC bio, New York, New York

Publisher

American Medical Association (AMA)

Subject

Ophthalmology

Link

https://jamanetwork.com/journals/jamaophthalmology/articlepdf/2768857/jamaophthalmology_khanani_2020_oi_200055_1600873409.8708.pdf

Reference29 articles.

1. Ten years of anti-vascular endothelial growth factor therapy.;Ferrara;Nat Rev Drug Discov,2016

2. Optimizing anti-VEGF treatment outcomes for patients with neovascular age-related macular degeneration.;Wykoff;J Manag Care Spec Pharm,2018

3. Real-world visual outcomes in patients with neovascular age-related macular degeneration receiving aflibercept at fixed intervals as per UK licence.;Ozturk;Clin Exp Ophthalmol,2018

4. The neovascular age-related macular degeneration database: multicenter study of 92?976 ranibizumab injections: report 1: visual acuity.;Writing Committee for the UK Age-Related Macular Degeneration EMR Users Group;Ophthalmology,2014

5. Multi-country real-life experience of anti-vascular endothelial growth factor therapy for wet age-related macular degeneration.;Holz;Br J Ophthalmol,2015

Cited by 125 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Comprehensive assessment of the impact of intravitreal faricimab on retinal diseases: A systematic review, meta-analysis, and trial sequential analysis;Pharmacological Research;2024-10

2. Faricimab in Previously Treated Eyes With Neovascular Age-Related Macular Degeneration: An Assessment of Durability and Treatment Outcomes;Ophthalmic Surgery, Lasers and Imaging Retina;2024-09

3. Dual pathway inhibition with faricimab for previously treated neovascular age-related macular degeneration and diabetic macular oedema: guidance from a UK panel of retina specialists;Eye;2024-08-30

4. Short-term Outcomes of Faricimab for Neovascular Age-related Macular Degeneration with Limited Response to Ranibizumab or Aflibercept;Journal of the Korean Ophthalmological Society;2024-08-15